{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Knowledge, Attitude and Practice Survey to understand the perceptions of healthcare practitioners in Diabetes Mellitus management using newer Oral Antidiabetic Drugs (OADs) and their combinations, with an emphasis on CArdio-REnal advantages (DM-CARE Study)

Survey Questionnaire Form

Doctor’s Details

Questionnaire

  1. Which of the statements you agree the most related to Indian diabetic phenotype (more than one statement can be selected) ?*

  2. In what proportion of your T2DM patients do you consider continuous glucose monitoring (CGM)? *

  3. In which of the following scenarios, do you advice for continuous glucose monitoring in your patients with T2DM? *

  4. While using CGM in your diabetic patients – which parameter do you consider most important to determine efficacy of diabetes interventions? *

  5. How often do you estimate HbA1c after initiating T2DM treatment? *

  6. As diabetes is a cardiovascular risk equivalent in general – do you believe more specifically diabetes increases risk of Heart Failure ? *

  7. What proportion of your T2DM patients have cardiovascular comorbidities? *

  8. How do you generally assess cardiovascular comorbidities in your patients with T2DM? *

  9. What proportion of your T2DM patients have renal comorbidities? *

  10. How do you generally assess renal comorbidities in your patients with T2DM? *

  11. How do you compare risk of Chronic Kidney Disease (CKD) as compared to Heart Failure in your diabetic patient population? *

  12. Do you feel beyond tight glycemic control there is need for cardio-renal protection by anti-diabetic agents early on in diabetes management? *

  13. Which among the newer oral antidiabetic medications viz. SGLT2 inhibitors and DPP4 inhibitors you consider is more efficacious? *

  14. On patients uncontrolled on Metformin, which of the class would you like to initiate first among DPP4 inhibitors and SGLT2 Inhibitors? *

  15. According to you, initial usage of SUs would be replaced by which class of drug – DPP4 Inhibitors or SGLT2 Inhibitors? *

  16. In diabetes patient with established ASCVD or heart failure, which class of the drug will be preferred by you as add on to metformin? *

  17. In diabetes patients with CKD, which class of the drug will be preferred by you as add on to metformin? *

  18. Among elderly diabetic patients without comorbidities such as CKD or HF, which of the class would you prefer taking into consideration the safety aspects? *

  19. With respect to the FDCs of SGLT2i + DPP4i which of the following parameters you find most important? *

  20. Kindly rate the following newer FDC’s of antidiabetic medicines? *
    (Rate 1-5, 1= Least important and 5= Most Important)
    21. a. SU + Metformin + DPP4i
    b. SU + Metformin + SGLT2i
    c. DPP4i + Metformin + SGLT2i
    d. DPP4i + SGLT2i
  21. In what proportion of your uncontrolled T2D patients you would consider using fixed dose combination of SGLT2i and DPP4i? *

  22. In which of the following diabetic patient profile/s you would consider use of FDC of SGLT2i + SU + Metformin? (more than one option can be selected)*

  23. In which of the following diabetic patient profile/s you would consider use of FDC of DPP4i+ SU + Metformin? (more than one option can be selected)*

  24. What proportion of your T2DM patients requiring insulin would be on? *
    25. a. Human Insulin (fast acting, intermediate acting and premix)
    b. Basal Insulin
    c. Insulin analogs (include fast acting, intermediate acting and pre-mix)
    d. Any other
  25. Finerenone (non-steroidal MRA) should be used as add on in diabetes patients with CKD ? *

  26. In your diabetes patients with CKD which of the following you add to existing therapies? *

  27. In which stages of CKD, would you consider adding finerenone to treatment in type 2 diabetes patients? *